Cancer is is now the number one cause of death among the population in our country. Bone is the third most common site of metastasis after lung and liver. The survival rate of malignant tumor patients has improved significantly in recent years, and the chance of developing distant metastases has increased significantly, while the prolongation of the median survival time makes patients face a greater chance of bone complications. Due to the lack of training in diagnostic knowledge related to orthopedic diseases, medical oncologists, when faced with a history of cancer and concurrent orthopedic lesions, have difficulty determining whether it is a bone-related event of cancer or a primary disease of the bone and when orthopedic surgical intervention is needed. Therefore, the promotion of standardized multidisciplinary discussions can better rationalize the use of medical resources and benefit the majority of cancer patients in the diagnosis and treatment of bone metastatic cancer. Systemic antitumor therapy (chemotherapy, biotargeted therapy, etc.), analgesic therapy, bisphosphonate therapy and RANKL monoclonal antibody denosumab, surgical therapy, and radiation therapy are several therapeutic approaches that can be used in the treatment of bone metastases (including the prevention of bone-related events) in order to improve the quality of survival. Currently, the goals of orthopedic surgical treatment are considered to be symptomatic relief, improved quality of survival, maintenance or restoration of bone integrity, maintenance or restoration of motor function, elimination or prevention of neurologic damage, and shorter hospitalization or rehabilitation time. It is recommended that multidisciplinary guidance is needed to confirm the diagnosis of metastatic bone cancer and to select the appropriate timing of surgical intervention; treatment planning for metastatic bone cancer needs to take into account life expectancy, tumor type and stage, the presence or absence of visceral metastases, the Kahlil’s Physical Status Score (KPS), the time from primary to the appearance of metastases, the risk of pathological fracture, and predictions of sensitivity to chemotherapy, hormones, and radiation therapy.